These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36928864)

  • 1. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
    Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
    Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients.
    Cholongitas E; Oikonomou T; Bafa K; Sinakos E; Papatheodoridis GV; Goulis I
    Transplantation; 2024 Sep; 108(9):e239-e244. PubMed ID: 38557857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?
    Ferenci P; Reiberger T; Stadlbauer V; Zoller H
    Liver Int; 2023 Aug; 43 Suppl 1():96-100. PubMed ID: 35767373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
    Rodríguez-Tajes S; García-Eliz M; Marcos AC; Campos-Varela I; Ros AC; Loinaz C; Gómez Bravo MÁ; Rodríguez-Perálvarez M; Fabrega E; González Diéguez ML; Vinaixa C; Pascasio JM; Vázquez IF; Baliellas C; Castells L; Salcedo M; Prieto M; Crespo G; Lens S; Forns X
    Liver Int; 2024 Feb; 44(2):279-285. PubMed ID: 38100141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
    Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
    Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
    Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation.
    Battistella S; Zanetto A; Gambato M; Germani G; Senzolo M; Burra P; Russo FP
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts.
    Orfanidou A; Papatheodoridis GV; Cholongitas E
    Liver Int; 2021 Jul; 41(7):1448-1461. PubMed ID: 33656809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation.
    Duvoux C; Belli LS; Fung J; Angelico M; Buti M; Coilly A; Cortesi P; Durand F; Féray C; Fondevila C; Lebray P; Martini S; Nevens F; Polak WG; Rizzetto M; Volpes R; Zoulim F; Samuel D; Berenguer M
    Aliment Pharmacol Ther; 2021 Sep; 54(5):583-605. PubMed ID: 34287994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
    Radhakrishnan K; Chi A; Quan DJ; Roberts JP; Terrault NA
    Transplantation; 2017 Sep; 101(9):2079-2082. PubMed ID: 28880197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.